Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus

Phase 2 Terminated 22 enrolled Charles Drew University of Medicine and Science

RandomizedParallel-groupOpen-labelTreatment

Summary

A 4-month, randomized, prospective, open-label comparison trial of hydroxychloroquine vs. pioglitazone in type 2 diabetic patients inadequately controlled on maximally tolerated doses of metformin plus a sulfonylurea.

Timeline

Start: 2014-11
Primary completion: 2017-11
Completion: 2017-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Hydroxychloroquine	Small molecule	400 mg	Oral
Comparator	Pioglitazone	Small molecule	45 mg	Oral

Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus

Summary

Timeline

Drugs

Indications